Application of ML216 in the preparation of drugs against porcine deltacoronavirus
By using ML216 as a helicase inhibitor, the helicase activity of pig Delta coronavirus was inhibited, and the problem of lack of effective antiviral drugs in the prior art was solved, effective control of PDCoV was achieved, and the chicken embryo was significantly extended Survival time and reduce mortality.
Patent Information
- Application Number
- CN202410859766.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-28
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-06-28
AI Technical Summary
There are currently no effective vaccines and antiviral drugs to control pig delta coronavirus (PDCoV) infection, and no specific drugs for PDCoV have been developed.
ML216 is used as a helicase inhibitor to inhibit the helicase activity of the virus and achieve the effect of antiviral control of PDCoV infection.
ML216 significantly inhibits the infection and proliferation of PDCoV in in vitro experiments, prolongs the death time of chicken embryos and reduces mortality, providing a new antiviral drug preparation scheme.
Smart Images

Figure CN118593490B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to the application of ML216 in the preparation of anti-swine delta coronavirus drugs. Background Art
[0002] Porcine delta coronavirus (PDCoV) is a new type of enteropathogenic coronavirus in pigs, which can cause watery diarrhea, vomiting and even death in piglets aged 5 to 15 days. Pigs of all ages are susceptible to PDCoV, and PDCoV can not only infect pigs alone and make them sick, but also co-infect with other pathogenic viruses, such as porcine epidemic diarrhea virus (PEDV) and porcine transmissible gastroenteritis virus (TGEV), with a co-infection rate of 44.4%. Since its discovery, PDCoV has caused huge economic losses to the pig farming industry in various countries, and there is currently no effective vaccine or antiviral drug to control PDCoV infection.
[0003] PDCoV belongs to the genus Deltavirus of the Coronaviridae family. It is an enveloped, positive-sense single-stranded RNA virus with a genome length of 25.4kb, the smallest genome among known coronaviruses. The morphology of its virus particles is polymorphic, and there are several rod-shaped protrusions on the outer membrane, which are in a typical "crown" shape. PDCoV encodes four major structural proteins, namely spike glycoprotein (S), envelope protein (E), membrane protein (M) and nucleocapsid protein, and also encodes three auxiliary proteins, NS6, NS7 and NS7a. A lot of research has been done on the development of PDCoV drugs at home and abroad, but no particularly effective specific drugs have been developed, which has also brought severe challenges to the prevention and treatment of the disease.
[0004] ML216 [1-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl)urea] is a small molecule inhibitor of the helicase activity of BLM (Bloom's syndrome protein), which is a member of the RecQ DNA helicase family. Bloom syndrome caused by BLM mutations is associated with cancer susceptibility, growth retardation, immunodeficiency, sunlight sensitivity and fertility defects. Compared with other members of the RecQ family, ML216 is selective for BLM, especially in vivo. ML216 may act at the BLM nucleic acid substrate binding site, inhibit DNA binding and block the helicase activity of BLM, inhibiting cell proliferation. Based on this, ML216 has received widespread attention in the treatment of cancer and other related diseases or conditions. For example, Xiao-Yan Ma, Jia-Fu Zhao et al. revealed that the combination of ML216 and cisplatin (a DNA cross-linking agent) showed synergistic effects in prostate cancer cells and could enhance the anti-tumor effect (DOI: 10.3390 / molecules27248790); ML216 was also studied for use in combination with PARP inhibitors, and had a radiosensitizing effect in non-small cell lung cancer; Yangyang Kong, Chang Xu et al. revealed that when ML216 was used in combination with PARP inhibitors, it showed a radiosensitizing effect in non-small cell lung cancer (NSCLC) cells (DOI: 10.20892 / j.issn.2095-3941.2021.0178); Chinese patent document CN113797338B discloses DBC1 regulation of cell senescence and its application, and provides the application of ML216 in the preparation of drugs for preventing or treating aging-related diseases or disorders, including lung diseases and disorders, kidney diseases and disorders. However, there has been no report on the use of ML216 for treating various diseases or conditions caused by viruses. Summary of the invention
[0005] In view of the above-mentioned problem that there is currently no effective vaccine and antiviral drug to control PDCoV infection, and no specific drug for PDCoV has been developed, the present invention provides the use of ML216 in the preparation of anti-swine deltacoronavirus drugs, and verifies for the first time that ML216 can inhibit the viral helicase and achieve the antiviral effect of controlling PDCoV infection.
[0006] One of the purposes of the present invention is to provide the use of ML216 as a helicase inhibitor in the preparation of drugs for treating or preventing viral infections.
[0007] Preferably, in the aforementioned application, the virus is a porcine virus, further preferably a porcine coronavirus, and most preferably a porcine deltacoronavirus (PDCoV).
[0008] Preferably, in the aforementioned application, the ML216 is used as an active ingredient or one of the active ingredients in the fight against porcine deltacoronavirus (PDCoV).
[0009] The second object of the present invention is to provide the use of ML216 in a product or method for inhibiting porcine deltacoronavirus for non-therapeutic purposes.
[0010] Beneficial effects of the present invention:
[0011] 1) The present invention discovered for the first time that ML216 has the effect of inhibiting viral infection in vitro, providing a new solution and new idea for the preparation of antiviral drugs.
[0012] 2) The present invention comprehensively utilizes cell biology and virology technologies to discover and verify for the first time that ML216 has the effect of inhibiting PDCoV infection in vitro, providing a new solution and new ideas for the control and treatment of PDCoV.
[0013] 3) The present invention provides the use of ML216 in the preparation of anti-swine delta coronavirus drugs.
[0014] 4) The present invention used LLC-PK1 cells and chicken embryos to verify the cytotoxicity of ML216 and its inhibitory effect on PDCoV. The results showed that ML216 at a concentration of 100 μg / kg could significantly prolong the death time of chicken embryos and reduce the mortality rate.
[0015] 5) The present invention verifies for the first time that ML216, as a helicase inhibitor, has antiviral proliferation effects and can be used as an effective ingredient or one of the effective ingredients in the preparation of drugs for the treatment and prevention of porcine delta coronavirus or for research and application for non-therapeutic purposes. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The results of the cytotoxicity test of ML216 on LLC-PK1 cells were identified;
[0017] Figure 2 The results of the indirect fluorescence immunoassay of LLC-PK1 cells infected with PDCoV by ML216;
[0018] Figure 3 5μM, 10μM, and 20μM ML216 inhibited PDCoV proliferation;
[0019] Figure 4 5μM, 10μM, 20μM ML216 inhibits PDCoV proliferation TCID 50Determination;
[0020] Figure 5 This is the stage of ML216 inhibiting the proliferation of PDCoV;
[0021] Figure 6 This is the survival curve of chicken embryos infected with PDCoV under the action of ML216 compound;
[0022] Figure 7 This is the bleeding situation of chicken embryos infected with PDCoV under the action of ML216 compound. DETAILED DESCRIPTION
[0023] The specific embodiments of the present invention are further described in detail below in conjunction with the examples. The reagents not cited in the following experiments are all commercially available reagents, and the methods not described in detail are all conventional well-known experimental methods. The full name of the compound ML216 involved in each example is ML216 [1-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl)urea], its CAS number is 1430213-30-1, and its structural formula is:
[0024]
[0025] The present invention uses ML216 to verify and illustrate the inhibitory effect of porcine deltacoronavirus (PDCoV) in detail, which does not mean that ML216 only has an inhibitory effect on PDCoV. The purpose of the embodiment is to illustrate that ML216 has a certain inhibitory effect on porcine viruses including other coronaviruses and even other non-porcine viruses, and can be used as a drug or technology for therapeutic or non-therapeutic purposes. The specific embodiments are as follows:
[0026] Example 1: Identification of ML216 Cytotoxicity to LLC-PK1 Cells
[0027] LLC-PK1 cells were grown in a 37°C, 5% CO2 incubator. After the cells in the culture flask were full, LLC-PK1 cells were spread on a 96-well cell culture plate at 2.5×10^5 cells / mL, and 100 μL of MEM medium containing 10% (v / v) heat-inactivated fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin was added to each well, and cultured in a 37°C, 5% CO2 incubator; after the cells were full, the original cell culture medium was removed and replaced with 0 μM, 5 μM, 10 μM, 20 μM, 50 μM, 100 μM, 200 μM, ML216 compound MEM culture medium, incubated at 37°C for 24 hours, and then 2% FBS MEM medium was added to dilute the cck-8 reagent (1:10), mixed well, and added to each well and cultured in a 37°C, 5% CO2 incubator for 2 hours; cytotoxicity identification was performed according to the operating instructions.
[0028] The results are as follows Figure 1 As shown, the cell activity of 200 μM ML216 on LLC-PK1 cells was higher than 100%, indicating that ML216 had no cytotoxicity. When using lower drug concentrations, better antiviral effects were obtained, so the concentrations of the compounds selected for subsequent virus effectiveness verification experiments were 5 μM, 10 μM, and 20 μM.
[0029] Example 2: Verification of the inhibitory effect of ML216 on LLC-PK1 cells infected with PDCoV
[0030] LLC-PK1 cells were cultured according to the method of Example 1. After LLC-PK1 cells were fully grown, they were plated at 2.5×10^5 cells / mL on a 24-well culture plate containing a cell slide. 1 mL of MEM culture medium containing 10% (v / v) heat-inactivated fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin was added to each well. The cells were incubated at 37°C and 5% The cells were cultured in a CO2 incubator for 36 h; a solvent group (methyl sulfoxide, DMSO), a positive control group (lycorine, LH), a blank control group (MEM culture medium), and a group containing 5 μM, 10 μM, and 20 μM ML216 compounds were set up respectively, and the LLC-PK1 cells were infected with the PDCoV-CHN-2014 strain at a virus infection multiplicity (MOI) of 0.1 at 37°C for 2 h; the cell supernatant was discarded, and the cells were washed three times with phosphate buffer (1*PBS) to wash away the virus particles that did not invade the cells; the culture medium containing 5 μM, 10 μM, and 20 μM ML216 compounds was added again and incubated for 12 h, then the cells were fixed with 4% paraformaldehyde, incubated with PDCoV N antibody at room temperature for 2 h, incubated with fluorescent secondary antibody in the dark for 1 h, incubated with DAPI for 15 min, and the results were observed with an Olympus BX63 fully electric upright fluorescence microscope.
[0031] The results are as follows Figure 2 As shown, the solvent (DMSO) has no antiviral effect. Under the conditions that the positive results of the experiment and the blank control are established, the compound ML216 has different degrees of inhibitory effect on PDCoV at concentrations of 5μM, 10μM, and 20μM of ML216, among which the inhibitory effect is extremely obvious at the concentration of 20μM, and it is obviously concentration-dependent with increasing concentration.
[0032] Example 3: Effect of ML216 on LLC-PK1 infection with PDCoV N gene copy number
[0033] LLC-PK1 cells were plated in a 24-well cell culture plate at 2.5×10^5 cells / mL, and 1 mL of MEM medium containing 10% (v / v) heat-inactivated fetal bovine serum, 100U / mL penicillin, and 100μg / mL streptomycin was added to each well, and cultured in a 37°C, 5% CO2 incubator for 36 hours; new serum-free MEM medium was replaced, and LLC-KPK1 cells were infected with the PDCoV-CHN-2014 strain at a virus infection multiplicity (MOI) of 0.1 at 37°C for 2 hours; the cell supernatant was discarded, and the cells were washed three times with phosphate buffer (1*PBS) to wash away the virus particles that did not invade the cells; 1 mL of MEM medium with ML216 concentrations of 0μM, 5μM, 10μM, and 20μM was added to the wells of the cell culture plate, and cultured at 37°C for 18 hours.
[0034] The cells were collected, the cell supernatant was discarded, and the cells were washed three times with 1*PBS; the total RNA of PDCoV infected cells was extracted using RNA extraction reagent Trizol, and complementary DNA (cDNA) was generated using Prime Script RT Master Mix reverse transcription kit as qRT-PCR template; the PDCoV nucleocapsid protein (N) RNA content was measured by absolute qRT-PCR to represent the viral RNA content of infected cells; the primers and reaction system are shown in Tables 1 and 2; the staining method fluorescence quantitative premix AceQ Universal SYBR qPCR master Mix; the reaction program used the Fast program that comes with the ABI fluorescence quantitative PCR instrument.
[0035] Table 1. RT-qPCR primers are as follows
[0036]
[0037] Table 2. Reaction system and procedure
[0038]
[0039] The experiment was performed three times independently, with three replicates each time. The experimental data were expressed as group mean and standard deviation (SD).
[0040] GraphPad Prism 8.0 software was used for unpaired, two-tailed Student t test; ***p<0.001 indicated extremely significant statistical differences.
[0041] The results are as follows Figure 3 As shown, 0μM, 5μM, 10μM, and 20μM compound ML216 reduced the copy number of PDCoV N protein in a concentration-dependent manner, and 20μM compound ML216 had the most obvious inhibitory effect on PDCoV.
[0042] Example 4: Effect of PDCoV on PDCoV virus titer in LLC-PK1 cells infected with PDCoV
[0043] In order to further confirm that ML216 inhibits the infection of LLC-PK1 cells with PDCoV, LLC-PK1 cells were cultured according to Example 1; new MEM medium was replaced, and the PDCoV-CHN-2014 strain was infected at a virus infection multiplicity (MOI) of 0.1 at 37°C for 2 h, the cell supernatant was discarded, the cells were washed three times with phosphate buffer (1*PBS) to wash away the virus particles that did not invade the cells, and 1 mL of MEM medium with ML216 concentrations of 0 μM, 5 μM, 10 μM, and 20 μM was added to the wells of the cell culture plate, respectively, and samples were collected 12 h after virus infection, and the collected virus samples were repeatedly frozen and thawed three times, centrifuged at 4°C and 12000 rpm for 15 min, and the supernatant was taken, and the TCID 50 The experiment detects the virus content in the sample.
[0044] The results are as follows Figure 4 As shown, 5μM, 10μM, and 20μM compound ML216 had an inhibitory effect on PDCoV, and the effect decreased in a concentration-dependent manner. The inhibitory effect of 20μM compound ML216 on PDCoV was the most obvious.
[0045] Example 5: Schematic diagram of the inhibitory effect of ML216 on PDCoV at different stages of action
[0046] The experimental methods for different proliferation stages are as follows:
[0047] (1) Adsorption stage: LLC-PK1 cells in 6-well plates were exposed to different concentrations of compounds at 0 μM ML216, 10 μM ML216, and 20 μM ML216. They were pretreated at 37°C for 1 hour, then at 4°C for 30 min, and washed three times with 1*PBS. PDCoV-CHN-2014 was mixed with 10 μM ML216 and 20 μM ML216 at an MOI of 0.1, incubated at 4°C for 1 hour, the culture medium was discarded, the cells were washed three times with 1*PBS, and the cell lysate was collected for qRT-PCR.
[0048] (2) Internalization stage: After LLC-PK1 cells have grown to full size, they are inoculated with 0.1 MOI of PdCoV and incubated at 4°C for 1 hour to discard the unadsorbed virus and wash three times with PBS. The medium is replaced with medium containing 0 μM, 10 μM, and 20 μM concentrations of ML216 compound and the cells are incubated at 4°C for 1 hour to promote the action of the compound. The cells are then transferred to 37°C and incubated for 1 hour. The supernatant is discarded and the cells are washed three times with PBS to collect the cell lysate for qRT-PCR.
[0049] (3) Replication stage: After LLC-PK1 cells are fully grown, they are inoculated with 0.1 MOI of PdCoV and incubated at 37°C for 2 h. The culture medium is discarded and culture medium containing 0 μM, 10 μM, and 20 μM ML216 compound is added. The cells are incubated at 37°C for 6 h and samples are collected at 6, 7, 8, 9, and 10 h. The TCID 50 Detect virus titer.
[0050] (4) Release phase: LLC-PK1 cells were inoculated into 24-well cell culture plates, and PDCoV (0.1 MOI) was inoculated after the cells grew into a monolayer, adsorbed at 37°C for 2 h, washed three times with PBS, and infected for 18 h with fresh culture medium containing trypsin (collect the supernatant), and then replaced with fresh culture medium containing 0 μM, 10 μM, and 20 μM of the compound. The supernatant and cell lysate were collected at 15 min, 30 min, 45 min, and 60 min after the culture medium was replaced. The amount of virus was detected by qRT-PCR.
[0051] After collecting the cell culture fluid and supernatant, the uninfected LLC-PK1 cells were diluted to 2.5×10^5 cells / mL and laid on a 96-well cell culture plate. 100 μL of MEM culture medium was added to each well and placed in a 37°C, 5% CO2 incubator for overnight culture; the supernatant of the cells infected for 16 hours was diluted 10 times and inoculated with LLC-PK1 cells laid on a 96-well cell culture plate, 100 μL was inoculated in each well, and 8 replicates were made for each dilution. In addition, the supernatant of LLC-PK1 cells infected with PDCoV without ML216 treatment was used as a control; the 96-well cell culture plate was placed in a 37°C, 5% CO2 incubator for culture; the cell growth status was observed every 24 hours, and the number of cytopathic wells was recorded for 2 days until the number of cytopathic wells no longer increased; the TCID of the virus was calculated using the Reed-Muench method 50 ; The experimental data were expressed as group mean and standard deviation (SD), and statistical analysis was performed using Graph Pad Prism 8.0 software with unpaired, two-tailed Student t-test; ***p<0.001 indicated a very significant statistical difference.
[0052] The results are as follows Figure 5 As shown, under the action of 10μM and 20μM compounds, the copy number of PDCoV N protein in the virus adsorption stage and internalization stage was not significantly different from that in the virus infection group alone; at 10μM and 20μM ML216, the copy number of PDCoV N protein was significantly reduced at the 9th and 10th hours after virus infection, indicating that compound ML216 inhibited the virus replication stage; at 10μM and 20μM ML216, there was a significant inhibitory effect in the virus release stage.
[0053] Example 6: Detection of antiviral activity of ML216 in SPF chicken embryos
[0054] The antiviral activity of compound ML216 was tested in SPF chicken embryos. The specific steps are as follows:
[0055] (1) Incubate SPF chicken embryos to 5 days old, turning the eggs three times a day to maintain the vitality of the chicken embryos;
[0056] (2) Before infecting chicken embryos, select chicken embryos with better vitality by egg scanning, and draw the air chamber and inoculation position;
[0057] (3) Compound ML216 (20 μM / L) was diluted to 500 μg / kg and 100 μg / kg, and PDCoV was diluted to 10 4.5 TCID50, mixed with diluted compounds. Set up blank control group (Mock), infection group (PDCoV-CHN-2014), and ML216 treatment group (500μg / kg ML216+PDCoV-CHN-2014, 100μg / kg ML216+PDCoV-CHN-2014).
[0058] (4) The marked chicken embryos were disinfected with 75% alcohol, punched and inoculated, and the premixed solution of each group was inoculated into the chicken embryo allantoic fluid with a syringe (100 μL was inoculated into each chicken embryo), and the holes were sealed with paraffin and marked.
[0059] (5) Place the inoculated chick embryos in a 37°C constant temperature incubator and observe for 24 hours. Use an egg candling device to check the survival of the chick embryos. If there is no death of the chick embryos within 24 hours, it indicates that the operation is correct. After 24 hours, observe the condition of the chick embryos every 3 hours and collect dead chick embryos in time.
[0060] (6) The air sac chamber of the chicken embryo was opened, and 500 μL of allantoic fluid was taken from each chicken embryo and frozen and thawed once at -20°C. The allantoic fluid was used to detect the chicken embryo PDCoV titer and PDCoV RNA level (PDCoV N gene was used as a representative gene).
[0061] The results are as follows Figure 6 and Figure 7 As shown, compared with the PDCoV infection group, the groups treated with 500 μg / kg and 100 μg / kg ML216 compounds significantly prolonged the death time of chicken embryos, significantly reduced the mortality rate of chicken embryos, and significantly reduced the bleeding of chicken embryo bodies, which had a good therapeutic effect on the animal model susceptible to PDCoV.
[0062] It is obvious to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be regarded as exemplary and non-restrictive from any point of view. In addition, it should be understood that although this specification is described in accordance with the implementation mode, it does not include only one technical solution. This narrative mode of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole, and the technical solutions in the embodiments can also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.
Claims
1. Use of ML216 as a helicase inhibitor in the preparation of a drug for treating or preventing viral infection, wherein the virus is porcine deltacoronavirus; the structural formula of ML216 is: 。 2. The use according to claim 1, characterized in that: The ML216 is used as an active ingredient or one of the active ingredients in the fight against porcine delta coronavirus.
3. The use according to claim 2, characterized in that: The concentration of ML216 is 0.5-200 μM.
4. The use according to claim 3, characterized in that: The concentration of ML216 is 10-200 μM.
5. The use according to claim 1, characterized in that: The ML216 inhibits the replication and release phases of PDCoV.
